AIM Banners_978 x 90

Why Isomorphic Labs Partnered with Novartis and Eli Lilly 

This development comes at a time when NVIDIA recently introduced BioNeMo
Image by Nikhil Kumar
Isomorphic Labs, a London-based AI drug discovery startup, spun out of Google’s DeepMind unit just over two years ago, recently announced key partnerships with two of the world’s largest pharmaceutical companies — Eli Lilly & Co. and Novartis AG.  The deals are said to have a combined value of close to $3 billion. Isomorphic Labs will partner with Lilly for small molecule therapeutics, receiving an upfront payment of $45 million and up to $1.7 billion in milestone payments, excluding royalties. Similarly, with Novartis, Isomorphic Labs gets a $37.5 million upfront payment, funding for select research costs, and up to $1.2 billion in milestone payments, along with royalties on net sales. Founded in 2021 by Demis Hassabis, co-founder of DeepMind, Isomorphic Labs primaril
Subscribe or log in to Continue Reading

Uncompromising innovation. Timeless influence. Your support powers the future of independent tech journalism.

Already have an account? Sign In.

📣 Want to advertise in AIM? Book here

Picture of Siddharth Jindal
Siddharth Jindal
Siddharth is a media graduate who loves to explore tech through journalism and putting forward ideas worth pondering about in the era of artificial intelligence.
Related Posts
AIM Print and TV
Don’t Miss the Next Big Shift in AI.
Get one year subscription for ₹5999
Download the easiest way to
stay informed